ATE330972T1 - Apo-2l rezeptor-agonist und cpt-11 synergie- effekt - Google Patents

Apo-2l rezeptor-agonist und cpt-11 synergie- effekt

Info

Publication number
ATE330972T1
ATE330972T1 AT00941233T AT00941233T ATE330972T1 AT E330972 T1 ATE330972 T1 AT E330972T1 AT 00941233 T AT00941233 T AT 00941233T AT 00941233 T AT00941233 T AT 00941233T AT E330972 T1 ATE330972 T1 AT E330972T1
Authority
AT
Austria
Prior art keywords
cpt
apo
receptor agonist
synergy effect
synergy
Prior art date
Application number
AT00941233T
Other languages
English (en)
Inventor
Avi J Ashkenazi
Mark C Benyunes
Ralph H Schwall
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE330972T1 publication Critical patent/ATE330972T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00941233T 1999-06-09 2000-06-07 Apo-2l rezeptor-agonist und cpt-11 synergie- effekt ATE330972T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13824099P 1999-06-09 1999-06-09

Publications (1)

Publication Number Publication Date
ATE330972T1 true ATE330972T1 (de) 2006-07-15

Family

ID=22481115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941233T ATE330972T1 (de) 1999-06-09 2000-06-07 Apo-2l rezeptor-agonist und cpt-11 synergie- effekt

Country Status (13)

Country Link
US (3) US20040228868A1 (de)
EP (1) EP1192185B1 (de)
JP (1) JP2003505344A (de)
AT (1) ATE330972T1 (de)
AU (1) AU5596500A (de)
CA (1) CA2375149A1 (de)
DE (1) DE60028971T2 (de)
DK (1) DK1192185T3 (de)
ES (1) ES2267547T3 (de)
IL (1) IL146491A0 (de)
PT (1) PT1192185E (de)
WO (1) WO2000075191A2 (de)
ZA (1) ZA200002867B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
JP2002543151A (ja) * 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002009755A2 (en) * 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
EP1506285B1 (de) * 2001-11-01 2010-12-08 Uab Research Foundation Kombinationen aus anti-dr5-antikörpern und anti-dr4-antikörpern und weiteren therapeutischen agentien
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
KR20050065587A (ko) * 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
EP1710255A4 (de) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 The Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP2684896A1 (de) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
CN104203570B (zh) * 2012-08-03 2017-08-25 马自达汽车株式会社 透明叠层体及其制造方法
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
PT981618E (pt) * 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
JP2003505344A (ja) 2003-02-12
ES2267547T3 (es) 2007-03-16
EP1192185A2 (de) 2002-04-03
CA2375149A1 (en) 2000-12-14
ZA200002867B (en) 2001-12-07
US20040228868A1 (en) 2004-11-18
DE60028971D1 (de) 2006-08-03
IL146491A0 (en) 2002-07-25
US20090041788A1 (en) 2009-02-12
DE60028971T2 (de) 2007-02-08
PT1192185E (pt) 2006-11-30
US20070026000A1 (en) 2007-02-01
AU5596500A (en) 2000-12-28
WO2000075191A3 (en) 2001-05-10
DK1192185T3 (da) 2006-10-23
WO2000075191A2 (en) 2000-12-14
EP1192185B1 (de) 2006-06-21

Similar Documents

Publication Publication Date Title
DE60028971D1 (de) Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
EA200101166A1 (ru) Ингибиторы металлопротеаз
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
AP2002002458A0 (en) Compounds for the treatment of ischemia.
NI200800060A (es) Bencimidazoles sustituidos como inhibidores de cinasa.
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
ECSP055818A (es) Métodos y composiciones para inducir apoptosis en células de cáncer.
ID25853A (id) Penghambat saluran kalium
ATE113837T1 (de) Mittel zur bekämpfung des schmerzes, der depression und zur beruhigung.
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
BRPI0506802A (pt) derivados de indol e uso destes como inibidores de quinase em inibidores de ikk2 particulares
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
SE9802208D0 (sv) Novel compounds
ATE344670T1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
TW200738288A (en) Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
TW200624125A (en) Compositions and methods for increasing HDL and HDL-2b levels
DK1660100T3 (da) Anti-tumorformuleringer der omfatter defibrotid alene eller i kombination med andre anti-tumormidler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1192185

Country of ref document: EP